Fosun Pharmaceutical (02196) drugs are newly included in the National Medical Insurance Catalogue and the Commercial Insurance Innovative Drug Catalogue

Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. According to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue (2025)” (hereinafter referred to as the “2025 National Health Insurance Catalogue”) issued by the National Health Security Administration and the Ministry of Human Resources and Social Security on December 7, 2025, and the first “Commercial Health Insurance Innovative Drug Catalogue (2025)” (hereinafter referred to as the “Commercial Insurance Innovative Drug Catalogue”), Shanghai Fosun Pharmaceutical (Group) Co., Ltd. and its holding subsidiaries/units (hereinafter referred to as the “Group”) Listed products were included for the first time or involved adjustments to the information notes. The relevant situation is now announced as follows:

The 2025 National Medical Insurance Catalogue and Commercial Insurance Innovative Drug Catalogue will be implemented on January 1, 2026. Among them, information such as specific medical insurance payment standards, medical insurance reimbursement rules, and the validity period of agreements for negotiated drugs in the 2025 National Health Insurance Catalogue must be based on information published by relevant government departments such as the National Health Security Administration.

The total sales volume for the aforementioned newly included drugs for 2024 and the first three quarters of 2025 was approximately RMB 401 million and RMB 892 million respectively, accounting for approximately 0.98% and 3.04% of the Group's revenue for the same period. This new inclusion in the 2025 National Health Insurance Catalogue/Commercial Insurance Innovative Drug List will help further enhance the accessibility of these drugs and reduce the burden of drug use on patients. It will also help promote the marketing and sales of such drugs, which is expected to have a positive impact on the Group's results in subsequent years.